Redefining the impact of nutrition on breast cancer incidence: is epigenetics involved?

Dorothy Teegarden1,2, Isabelle Romieu3 and Sophie A. Lelièvre2,4*

1Department of Nutrition Sciences, Stone Hall, Purdue University, West Lafayette, IN, 47907-1264, USA
2Oncological Sciences Center and Purdue University Center for Cancer Research, Purdue University, West Lafayette, IN, 47907, USA
3Nutrition and Metabolism Section, International Agency for Research on Cancer (IARC), 150 cours Albert Thomas, 69372, Lyon cedex 08, France
4Department of Basic Medical Sciences, Lynn Hall, Purdue University, West Lafayette, IN, 47907-2026, USA

Abstract
Breast cancer incidence is rising worldwide with an increase in aggressive neoplasias in young women. Possible factors involved include lifestyle changes, notably diet that is known to make an impact on gene transcription. However, among dietary factors, there is sufficient support for only greater body weight and alcohol consumption whereas numerous studies revealing an impact of specific diets and nutrients on breast cancer risk show conflicting results. Also, little information is available from middle- and low-income countries. The diversity of gene expression profiles found in breast cancers indicates that transcription control is critical for the outcome of the disease. This suggests the need for studies on nutrients that affect epigenetic mechanisms of transcription, such as DNA methylation and post-translational modifications of histones. In the present review, a new examination of the relationship between diet and breast cancer based on transcription control is proposed in light of epidemiological, animal and clinical studies. The mechanisms underlying the impact of diets on breast cancer development and factors that impede reaching clear conclusions are discussed. Understanding the interaction between nutrition and epigenetics (gene expression control via chromatin structure) is critical in light of the influence of diet during early stages of mammary gland development on breast cancer risk, suggesting a persistent effect on gene expression as shown by the influence of certain nutrients on DNA methylation. Successful development of breast cancer prevention strategies will require appropriate models, identification of biological markers for rapid assessment of preventive interventions, and coordinated worldwide research to discern the effects of diet.

Key words: Nutrition: Diet: Breast cancer: Epigenetics: Mammary gland

Triangular relationship: breast cancer incidence, gene transcription and nutrition

Burden of breast cancer
Globally an estimated 1.38 million new breast cancer cases were diagnosed in 2008, which represents 23% of all cancers1. Breast cancer is the most common cancer in women from high-income countries and its frequency has been rising in low- and middle-income (LMI) countries. The range of incidence worldwide is great, with high rates (above 80 per 100,000) in high-income regions of the world (with the exception of Japan) and low rates (less than 40 per 100,000) in most LMI regions. However, the mortality rate does not mirror that of incidence because of the more favourable survival from breast cancer in developed regions. Breast cancer ranks as the fifth cause of death from cancer overall (458,000 deaths in 2008). Yet, breast cancer is the leading cause of mortality by cancer among women from LMI countries, which is in part related to poor access to screening, diagnosis and treatment2.3. The increase in incidence and mortality observed in LMI countries is thought to be due to a variety of factors such as population growth, ageing, lifestyle changes, and migration to urban communities. Noticeably, it is a major public health concern that the incidence of breast cancer is rising among premenopausal women, with neoplasias more likely to display aggressive phenotypes and poor responses to therapy5,6.

Abbreviations: CpG, C-phosphate-G; ECM, extracellular matrix; ER, oestrogen receptor; IGF, insulin-like growth factor; LMI, low and middle income; miRNA, micro RNA; 1,25(OH)2D, 1,25-dihydroxyvitamin D; 25OHD, 25-hydroxyvitamin D; PR, progesterone receptor; RR, relative risk; VDR, vitamin D receptor; WCRF, World Cancer Research Fund.

*Corresponding author: Sophie A. Lelièvre, fax +1 765 494 0781, email lelievre@purdue.edu
The 20-year predictions for large increases in breast cancer incidence and mortality in LMI regions(1) substantiate the urgency of the WHO’s call for actions to support primary cancer prevention research and to develop effective strategies such as those that might be related to the environment, and particularly nutrition which has been reported to change along with breast cancer incidence(7).

A number of risk factors have been identified that could help explain breast cancer incidence in different countries and are listed in the WHO—International Agency for Research on Cancer cancer report(8). Interestingly, a majority of risk factors are linked to nutrition (for example, obesity, alcohol consumption, birth weight, height, onset of puberty and menopause). As illustrated in the next sections, epidemiological, animal and clinical studies provide insights into the role of specific nutrients as well as dietary patterns in the development of breast cancer. However, a clear understanding of the impact of foods on the development of neoplasms requires scrutinising the mechanisms of action involved and timing during the lifespan of specific dietary intakes.

Genomic impact of nutrition

The growing research field referred to as nutrigenomics summarises it all: nutrition makes an impact on the genome to such a degree that it is paramount to understand this interaction in detail to prevent health disorders and help the treatment of diseases. Nutrigenomics may well unravel how genetic variations (for example, SNP) and epigenetic alterations (i.e. modifications at the gene level unrelated to changes in DNA sequence), which both control gene expression, influence the requirements for nutrients as well as the response to nutrients(9). Such an understanding will be particularly important for several types of cancers that appear to be influenced by nutrition for their development, progression and/or recurrence(9). Breast cancer is cited among these nutrition-dependent cancers mainly because of the risk brought by an overweight status in postmenopausal women and alcohol consumption. However, there is much to learn regarding the influence of foods on the mammary gland before and during breast cancer development according to a plethora of reports. Many nutrients have been described to have a potential impact on the mammary gland and its tumorigenesis in population and animal studies, but thus far there is little consensus revealed by meta-analyses(10). Issues such as measurement error in nutritional assessment, the length of study and the timing of exposure may contribute to the discrepancy among studies that focus on nutrition and breast cancer. Another source of variation that is usually not taken into account is genomic diversity. Indeed, different forms of breast cancer can be identified through specific gene expression profiles which correspond to distinct disease outcomes and sensitivity to treatment(11). Importantly, an emerging view is that the type or form of breast cancer is determined at the time of its onset(12), suggesting that genetic and environmental factors that play a role in tumour initiation might also influence how the disease will progress.

Epigenetic regulation

Gene expression profiles are closely controlled through epigenetic changes that can be defined as variations in the chromatin environment of a gene. These changes include the post-translational modification of histones (notably methylation and acetylation of lysines) and alterations in the degree of methylation of certain gene promoters by addition of methyl groups on the cytosines of C-phosphate-G (CpG) islands (cytosine and guanine connected by a phosphodiester bond (CpG) dinucleotide clusters)(13). Such islands are currently defined as regions of DNA of more than 500 bp with a C+G content equal to or greater than 55% and observed CpG/expected CpG of 0.65(14). DNA methylation influences the type of histone modifications that will be introduced at the gene promoter. Also, regardless of whether a promoter can be methylated it will be wrapped with histones bearing specific modifications. The type of histone modification will create epigenetic marks, and the specificity of these marks will lead to the recruitment of factors that either create a dense chromatin (for example, via the addition of heterochromatin protein, HP1) that prevents access to the DNA by the transcription machinery, hence leading to gene silencing, or favour the access to DNA by the transcription machinery notably via the displacement of histones by chromatin remodelling factors, hence leading to increased gene expression(15) (Fig. 1).

Depending on the location and the type of epigenetic modifications, the impact of these alterations on the expression of a particular gene will vary, ranging from silencing to full capacity expression. The complexity of epigenetic control is illustrated by the many possibilities to modify histones. For example, epigenetic marks can be found at defined lysines (for example, methylation on K4, K9, K27, K36, K79 on histone 3 and K20 on histone 4) of histones that participate either in gene expression or in gene repression and there exist different degrees of modifications for a given mark (for example, mono-, di- or trimethylation of lysines)(16). Histone modifications are controlled by enzymes, such as methyltransferases, and protein complexes, such as polycomb complexes, for their chemical modifications. There are also proteins that sense histone modifications and further epigenetic changes at a gene promoter, like those involved in abnormal DNA hypermethylation characteristic of certain genes silenced in cancer(17). The possibility of combining bivalent marks (i.e. the presence on the same gene promoter of histone modifications that favour transcription and histone modifications that repress transcription) is of extreme importance in stem
Epigenetics and breast cancer

It has long been known that breast cancer development is associated with modifications in the gene transcription
profile. Since the discovery of tumour suppressors and oncogenes, and as a consequence of the development of genome-wide gene transcription analyses, a plethora of genes often involved in the regulation of cellular homeostasis (from proliferation to DNA repair and survival) has been implicated in the initiation and progression of cancer. In addition, the discovery of a variety of possible post-translational modifications of histones, the building blocks of chromatin, has shed new light on the mechanisms of gene transcription control and their importance in cancer. Efforts to prevent and treat neoplasias include epigenetic modifications to remodel the gene expression profile in cancer cells, with the goal notably to re-express tumour suppressors. Some success in the manipulation of the epigenome for treatment purposes is illustrated by US Food and Drug Administration approval to use agents that prevent DNA methylation in myeloma therapy; it has been followed by approval of the use of inhibitors of histone deacetylase for certain forms of lymphomas\(^{22,23}\).

Targeting epigenetic mechanisms for therapy was initiated following results from a large body of studies indicating that preventing chromatin compaction by hypomethylating DNA and/or by inducing histone acetylation reduced cancer progression\(^{22}\). Beyond the global attack on the epigenome by such systemic therapies, epigenetic alterations offer the prospect of targeting the expression of specific genes since each gene that changes expression may show modifications in histones and possibly DNA methylation in its promoter region. As discussed in the following sections, cancer development appears to be accompanied by permanent epigenetic modifications, suggesting an involvement of mechanisms such as DNA methylation. The mammary gland is subjected to different phases of development from life in utero to menopause; therefore, an important question to answer for breast cancer is during what periods of the lifespan and by what factors epigenetic modifications are introduced which then alter the risk of developing cancers.

The concept of permanent or long-term epigenetic modifications is critical to understand as it has enormous consequences for determining the effect of modifiable factors, such as diet, on the breast tissue and the development of cancer prevention strategies. ‘Permanent epigenetic modifications’ means, for instance, that the repression of transcription of specific genes will be sustained even if the factors originally responsible for the repressive state are no longer present. However, it might be possible to change these epigenetic modifications either naturally with the appropriate signals or therapeutically, thus unlocking the repression status. As we will discuss, the fact that nutrients might be capable of inducing permanent epigenetic modifications could explain why diets and foods can have an effect on breast cancer risk that is shown many years after their consumption, and even in the offspring.

### Epigenetic modifications and breast cancer initiation

In order to understand how nutrients could control breast cancer risk by influencing the epigenome, it is important to review current knowledge on the involvement of epigenetic changes in breast cancer development. There have been relatively few studies linking breast cancer risk factors and epigenetic alterations in genes involved in breast cancer. The paucity of information is linked to the fact that most studies have reported analyses done in tumour tissues and, thus, were focused on already developed cancers. There are, however, some interesting research avenues to clarify the role of epigenetic modifications in breast cancer development.

Logically, an active area of epigenetics research is to focus on tumour suppressors since these genes would have to be silenced to promote cancer development. \(BRCA1\) is a gene involved in the onset of breast cancer and, if mutated, it increases the lifetime risk of breast cancer development by \(45–85\)%\(^{24,25}\). Interestingly, the breast tissue of women with \(BRCA1\) mutations shows a different median DNA methylation index in a selected array of genes compared with non-\(BRCA1\) mutation carriers, suggesting that a high breast cancer risk is associated with a different epigenetic pattern compared with women with an average risk\(^{26}\). Not surprisingly, \(BRCA1\) has been found to be frequently hypermethylated in sporadic breast cancers\(^{26}\), indicating that even in the absence of mutation, epigenetic modifications linked to long-term silencing lead to shut-down of the expression of this important gene for breast cancer development. Another interesting area of investigation is the dysregulation of signalling pathways such as the complex wingless and integration site growth factor (Wnt) pathway that controls differentiation, proliferation and polarity. Negative regulators of the Wnt pathway, Wnt inhibitory factor (WIF)\(^{27}\) and Wnt inhibitor Dickkopf-3 (DKK3)\(^{28}\), display a hypermethylated promoter (conducive to gene silencing) in cancer. WIF1 methylation seems to be under the control of the DNA methyltransferases DNMT1 and DNMT3\(\beta\) that are associated with \textit{de novo} methylation, especially in ageing cells\(^{27}\). Other regulators of Wnt such as secreted frizzled-related protein 1 (SFRP1) and adenomatous polyposis coli (APC) have also been found to be methylated in breast cancer\(^{29}\). Thus, not only one element of a pathway, but also several up- and downstream components may be methylated on their gene promoter, ensuring the complete and sustained inactivation of that pathway.

In the breast, the status of the stroma (i.e. extracellular matrix (ECM), soluble factors and non-parenchymal cells present within the ECM) has been convincingly associated with the initiation and progression of cancer\(^{30}\). One of the current hypotheses is that fibroblasts, a major cellular compartment of the stroma involved in the making and modification of the ECM, are responsible for the modified stromal signalling that ultimately alters the epigenome of...
epithelial (parenchymal) cells\(^{15}\). Possible epigenetic modifications associated with early steps of breast tumorigenesis linked to the stroma include the hypermethylation of the TMS1 (target of methylation-induced silencing) gene promoter. TMS1 is involved in the control of ECM adhesion-dependent survival\(^{32,33}\). Unfortunately, examples of stroma-dependent changes in the epigenome of breast epithelial cells remain scarce. This field of research needs to be further developed in light of the influence that nutrients may have on the stroma by altering its exposure to hormones, promoting adiposity and triggering or reducing inflammatory pathways conducive to breast cancer development\(^{34}\).

Micro RNA (miRNA), the newly discovered class of RNA that control miRNA translation into proteins, have now been associated with breast cancer development. Not surprisingly, the promoters of genes coding for miRNA mir-9-1, mir-124a3, mir-148, mir-152, and mir-663 were found to be hypermethylated, in parallel to the hypermethylation of promoters of tumour suppressor genes, in primary breast cancers\(^{35}\). Thus, although miRNA are not part of epigenetic mechanisms of gene transcription (because they act downstream of chromatin), there is a strong epigenetic control of their expression upon cancer development that reinforces the direct epigenetic control observed for genes critical to prevent breast cancer development. The recent evidence that foods have an impact on miRNA expression\(^{36}\) expands the possibilities for nutrition to influence breast cancer risk via epigenetic effects.

If the transcription of key genes needs to change in order for a tumour to develop, it is important to identify the types of local epigenetic modifications involved. It is also important to know whether an epigenetic alteration is temporary or permanent for a given gene based on epigenetic marks, so that proper intervention strategies are designed. Ultimately, it should be possible to harness pathways critical for breast cancer prevention by linking the knowledge related to specific epigenetic alterations associated with breast tumour initiation and the identification of foods that have an impact on the breast tissue before the onset of tumour development.

**Effect of diet on epigenetic imprinting**

The possibility for epigenetic modifications to be passed through cell division and maintain the same expression level for specific genes can be referred to as imprinting. When epigenetic modifications occur in a parent and affect germ cells, they can be passed on to the next generation and propagated through cell division in the embryo. This particular phenomenon is known as ‘genomic imprinting’ and might be an explanation for why certain families display a high risk of developing cancer although no breast cancer susceptibility gene mutation has been identified. Also, if epigenetic modifications occur early in an individual’s life and in a particular organ, it can affect a portion of the organ in which cells continue to divide, creating a specific field with high risk of developing breast cancer (for example, an entire ductal system or lobe within the breast). In addition, there is no reason why external factors could not also modify the epigenome of non-dividing cells in a particular organ, hence altering future responses of these cells to external signalling factors. The difference compared with the previous two scenarios is that epigenetic modifications in non-dividing cells should not be transmissible to other cells; hence, there would be long-lasting epigenetic memory in these cells but no transmission of epigenetic marks to the next generation of these cells. Therefore, regardless of the stage of the mammary gland, necessary environmental factors such as foods are likely to exert profound epigenetic effects, with propagation of sustained epigenetic modifications likely when they occur during the three major development phases (fetal development, puberty, pregnancy) (Fig. 2). In the paragraphs below we give examples of how dietary intakes could differentially make an impact on cancer development depending on when during the lifespan a particular diet is followed.

Fetal programming, a period during which the methylation of genes will be modified by the parental profiles or exposure in *utero*, is a high-risk stage for abnormal derepression of imprinted genes. Indeed, following fertilisation the parental genomes undergo demethylation before *de novo* methylation. This period has been described as placing an individual at ‘increased risk of developing diseases as a result of intra-uterine constraint’\(^{37}\). If proper methylation did not occur during embryogenesis, certain genes might become expressed and lead to enhanced risk of cancer development, such as when the gene for the stimulation of proliferation of insulin-like growth factor (IGF)-2 becomes demethylated. Food components that make an impact on IGF-2 notably include soya isoflavones as described later in the present review.

A clear correlation between early impact of diet and cancer development has been obtained with animal models. Rats receiving higher levels of the micronutrient choline *in utero* compared with controls showed reduced tumour growth and longer survival. The effects on the genome included higher expression of genes associated with favourable prognosis for breast cancer and decreased expression of certain genes associated with unfavourable prognosis compared with the control group (i.e. with deficient choline supplementation during gestation)\(^{38}\).

The risk of developing diseases can continue for generations, such as in families with high incidence of breast cancer without a known breast cancer susceptibility gene mutation. On the other hand, the effect of exposure to certain risk factors for breast cancer later in life might be transient and disappear upon removal of the risk factor and mainly depend on the continuous presence of the implicated factors\(^{39}\). Examples of this include hormone...
replacement therapy, although the effects are still debated and may also be protective\(^{(40)}\), and hormonal contraception. Although several explanations exist for the duration of the ‘risk factor effect’ after the agent inducing the risk is gone, one possibility that we introduced earlier may be the existence of ‘permanent’ (or long-term) and temporary modifications in the epigenome. Indeed, it is currently accepted that epigenetic alterations that involve DNA methylation can be sustained\(^{(41)}\). Therefore dietary risk and protective factors that specifically make an impact on DNA methylation might be more readily associated with long-term effects.

The increasingly recognised impact of foods on the epigenome warrants exploration of whether diets or specific dietary components can contribute to epigenetic modifications associated with breast cancer development. Components of foods, including dietary fats and amino acids, have been reported to have an effect on mammary gland development\(^{(42–44)}\). Even though the impact of nutrition on epigenetics in the breast tissue remains largely unexplored\(^{(45)}\), preliminary work reveals that nutrients associated with variations in breast cancer risk can indeed have an effect on the epigenome.

**Diet and breast cancer**

The large body of literature on nutrition and breast cancer has been recently reviewed and summarised by an international panel gathered by the World Cancer Research Fund (WCRF)\(^{(46)}\). In reviewing the literature, it is important to consider a number of issues related to study design, model systems and interpretation of studies. These issues, along with scarce information on the interaction of the epigenome with the response to nutrients, lead to difficulty in understanding the impact of nutrients on breast cancer risk. First, the results of epidemiological studies need to be interpreted with caution, as they do not determine cause and effect. The size of the study, the lack of diversity in dietary habits analysed in each study, the measurement error in outcome variables, and individual variation in human genetics and lifestyle factors may limit the ability to measure the probably very small size effects due to diet. Human models used in epidemiological studies have the caveat that most cancers develop over a relatively long period of time and, thus, interventions related to primary prevention, i.e. to inhibit the development of abnormal tissue growth, cannot be determined in epidemiological studies or clinical trials as the length is not sufficient or the relevant window of exposure is not captured in the intervention trial to assess true prevention. Another important issue is the level of nutrients compared in studies pertaining to breast cancer risk. If this level is in the severely deficient range it might have multiple effects on the organism and breast cancer development might be a secondary consequence of the deficiency.

**Advantages and limitations of study designs**

Clinical trials investigating the impact of diet on breast cancer prevention are limited. There are a number of issues contributing to such paucity. As explained previously, studying cancer prevention requires lengthy trial...
periods as breast cancer generally takes years to develop and is influenced by critical periods in breast epithelial tissue growth, i.e. fetal development, adolescence and pregnancy. It has been suggested that the diet during adolescence is an important predisposing factor for breast cancer risk later in life\(^{(47,48)}\). Thus, nutritional exposures during pregnancy\(^{(49)}\) as well as during fetal development and adolescence alter breast cancer risk\(^{(50)}\). The comparison of risks across a broad range of dietary patterns as well as specific periods of life has not been thoroughly studied. In addition, a large number of participants is required to achieve a reasonable amount of cases for statistical analysis in randomised trials of undiagnosed subjects. Also, previous studies demonstrate that the selection of ‘at-risk’ populations does not represent cancer prevention because this population may be more likely to have already developed cancer\(^{(51)}\). The effects of diets may also vary based on race, menopausal status, tumour characterisation (oestrogen receptor (ER)-positive (ER +) or ER-negative (ER−)) and weight or BMI, and these factors are not always considered in the analysis or the interpretation of the results. Finally, it is difficult to maintain compliance to dietary regimens for long periods of time. Therefore it will be critical to identify biomarkers for very early signs of breast cancer development that can be utilised to rapidly determine the impact of environmental factors on breast cancer risk and the success of actions proposed to reduce breast cancer incidence.

Animal models offer advantages because of genetic similarities and better control of environmental influences, including diet. However, animal models used to study cancer prevention often lack relevance to human breast cancer development. Rodent models provide opportunities for genetic manipulation that bring important information about the molecular mechanisms that underlie cancer progression and environmental interventions. Unfortunately, results are not consistently reproducible in human trials. Cell-based studies also contribute significantly to our understanding of the molecular mechanisms of dietary components to alter specific cellular processes essential to breast tumour development. However, the breast epithelial cell models most commonly used are cancer cells and, thus, they do not mimic stages of human breast cancer initiation. Even if some cell lines represent early stages in the development of breast cancer, rarely are they utilised in a physiologically relevant manner since most studies use traditional cell monolayer cultures that lack tissue morphogenesis and, thus, do not reproduce the three-dimensional tissue architecture known to direct the expression of genes involved in normal differentiation\(^{(52)}\).

However, the use of animal and cell models is critical to the overall determination of the impact of diet on breast cancer progression because these models contribute to determining mechanisms. Animal studies provide information that could not be obtained with human populations, particularly because it is difficult to assess diet in epidemiological studies and to achieve and maintain prescribed diets in intervention studies, and because the impact of diet may be specific to early exposure (prenatal to adolescence) which requires extended intervention periods. In rodent models cancer is generally experimentally induced (usually by means of a chemical carcinogen or irradiation), leading to the generation of tumours in all the animals in a relatively short period of time, thereby reducing the number of animals and time, i.e. cost required. However, there are no adequate models of cancer prevention that are easily translatable to humans and results must be considered with caution. Similarly, in vitro cell model systems often used to decipher the mechanisms of action of nutrients lack the physiological relevance to breast cancer development. Nevertheless, both animal and cell models, in spite of their limitations, can bring important insights into the role played by foods in breast cancer development.

Therefore, it is important to consider the cumulative results from each of these imperfect model systems to garner sufficient information in reviewing and establishing firm conclusions on how foods might make an impact on the breast. To simplify the review of the literature presented in the next paragraphs, whenever applicable, the results from the different models are subdivided into specific diet/foods categories. Within these categories the role of diet in modifying breast cancer risk and the proposed underlying mechanisms and potential roles of the interaction of diet and the epigenome are discussed.

**Obesity**

**Epidemiological studies.** There is substantial support for obesity increasing the risk of a variety of cancers, including breast cancer. The WCRF review panel concluded that weight is one of the few factors that convincingly leads to an increase in breast cancer risk in postmenopausal women\(^{(56)}\). Measures of weight are generally BMI (kg/m\(^2\)), waist and hip circumferences, or waist:hip ratio. These assessments are not only indirect measures of increased adiposity, but they also provide information about body fat distribution. An analysis of cohort studies suggests that in postmenopausal women, the smallest waist circumference lowers breast cancer risk compared with the largest waist circumference and that there is a 24 % lower risk in women with the smallest waist:hip ratio\(^{(55)}\). However, further evidence suggests that the impact of obesity may be modified by race, as the relationship between BMI and breast cancer risk was noted in white but not African-American postmenopausal women\(^{(54)}\).

In contrast to the increased risk of breast cancer with obesity in postmenopausal women are reports that increased weight may protect premenopausal women from breast cancer. For example, the higher the BMI at 18 years of age, the lower the risk in premenopausal women in the overweight to obese category (BMI ≥ 25 kg/m\(^2\))
compared with a low BMI (< 20 kg/m²) (OR 0.76; 95% CI 0.63, 0.90)(54). Moreover, a BMI of ≥ 35 kg/m² (morbidly obese) compared with normal to low weight BMI of < 25 kg/m² is accompanied by a reduced breast cancer risk (OR 0.81; 95% CI 0.61, 1.06) in premenopausal women. Neither of these associations with breast cancer risk is modified by race(57). Thus, obesity makes an impact on the risk of breast cancer positively and negatively, depending on the menopausal status (or age).

The association between obesity and breast cancer risk may be, at least in part, dependent on tumour type. For example, waist and hip circumferences and waist:hip ratio were significantly associated with a 1.95– to 2.75-fold increased risk only for ER-breast cancer development in the Nurses’ Health Study II (n 45 799)(55). Also, high (≥ 35 kg/m²) BMI was associated with increased risk of ER- and progestrone receptor (PR)-positive (PR + ) tumours among postmenopausal African-American women compared with normal to low BMI (< 25 kg/m²), with an OR of 1.83 (95% CI 1.08, 3.09) (54). Moreover, a BMI of 35 kg/m² (OR 3.75 (95% CI 1.39, 10.10) and OR 5.45 (95% CI 0.99, 10.05). However, studies based on adult self-reports or maternal recall during the women’s adulthood (0.98; 95% CI 0.95, 1.01) did not report significant effects (P for heterogeneity between data sources 0.003)(62).

Birth length and head circumference from birth records were also positively associated with breast cancer risk (pooled RR per 1 SD increment: 1.06 (95% CI 1.03, 1.10) and 1.09 (95% CI 1.03, 1.15), respectively). These data emphasise the importance of recording birth weight and other birth anthropometric measures in a standardised manner to avoid misclassification related to recall.

The influence of maternal intake on adiposity in the offspring has also been investigated by studying the weight and BMI of monozygotic and dizygotic twins. Some of these studies suggested that height (which is a risk factor for breast cancer) and weight, but not BMI are influenced by the intra-uterine environment(63), although birth weight predicted higher BMI in other twin studies(64,65). Therefore, the epidemiological evidence to support a relationship between maternal BMI during pregnancy and the risk for obesity in the offspring, which confers a risk for breast cancer later in life, is suggestive but not definitive.

In summary, observational population studies suggest that breast cancer risk is increased in postmenopausal women with high BMI, waist circumference and waist:hip ratio. However, higher BMI may confer protection against breast cancer in premenopausal women. The distribution of the adiposity (central v. overall) may also influence the risk in addition to menopausal status and race. Finally, evidence supports that there may be a relationship between maternal BMI and offspring, but further evidence is required to clarify these relationships. Most interestingly, the fact that weight gain might be associated with a specific type of breast tumour suggests a link with determinants of breast cancer types, such as gene expression profile, which emphasises the need to study the relationship between obesity and epigenetics.

**Animal models**

It is particularly important to use animal models for nutrients or other lifestyle factors, such as obesity, that will not be tested for their impact in human trials because they lead to increased risk for diseases. It is now recognised that adipose tissue is not only a storage entity for excess energy in the form of TAG, but also functions as a source of hormones that could affect breast tissue homeostasis. Examples are found in the serum levels of the adipose tissue hormones leptin and adiponectin, which are positively and negatively, respectively, correlated with adiposity. These hormones are being explored as potential mediators or protectors of the development of breast cancer. In addition, obesity induces a state of chronic inflammation and greater adiposity is associated with insulin resistance and diabetes, which may play roles in the well-characterised relationship between obesity and
increased risk of several cancers, including breast cancer. Importantly, dietary energy restriction protects against the development of mammary tumours in mice, regardless of the energy nutrient limited in the study. Determining if there is a relationship between obesity and breast cancer risk is complicated, as obesity is associated with high-fat diets, and models of obesity have often employed high-fat diets to increase energy density and induce greater adiposity, complicating the interpretation of experimental results. Therefore, studies related to obesity are confounded by the interaction of obesity with high-fat diets and health consequences, such as diabetes, which makes it difficult to decipher the role, and related specific mechanisms, of obesity in the development of breast cancer.

Mechanisms

The mechanisms, explored thus far, by which obesity may increase breast cancer risk are diverse. Adiponectin, which is inversely related to fat mass, inhibits cell proliferation and suppresses angiogenesis and inflammation. Adiponectin levels are lower in the presence of breast cancer compared with controls in both pre- and postmenopausal women. Furthermore, tumours of women in the lowest tertile of serum adiponectin are larger and of higher grade compared with tumours of women in the other tertiles. In contrast, leptin, the serum levels of which are positively related to fat mass, may promote breast cancer progression. The ratio of serum levels of leptin to adiponectin may also be important. Other adipokines such as vascular endothelial growth factor, hepatocyte growth factor and heparin-binding epidermal growth factor-like growth factor also promote angiogenesis and, hence, could participate in breast cancer development.

Other well-studied mechanisms that might be associated with breast cancer development include factors involved in insulin resistance and diabetes, which are consequences of increased adiposity. Insulin promotes cell proliferation and increased uptake of energy substrates for cell proliferation. Consequently, high serum insulin levels that occur in insulin resistance and type 2 diabetes are suggested to play a role in the development of breast cancer. Indeed, a two-fold increase in breast cancer risk was noted in the highest tertile of serum baseline insulin levels compared with the lowest tertile in postmenopausal women. Furthermore, studies in animals showed that the insulin receptor and IGF receptor played a role in mammary carcinogenesis in a non-obese model of type 2 diabetes. Insulin sensitivity may also be controlled by the adipokines, further confounding the relationships between insulin and obesity. Inflammatory mediators, such as TNFα associated with high adiposity, may also play a role in promoting tumour development. Therefore, both animal models and strong mechanistic-based studies support that adipokines, insulin and inflammatory mediators may underlie the relationship between obesity and breast cancer, although the specific mediator(s) are not yet clearly defined.

It is particularly important to note that some of these mediators might also be involved in the impact that maternal obesity may have on the offspring to increase their propensity of not only being overweight but also of developing mammary tumours. The well-known consequences of obesity proposed to increase the risk of breast cancer in adults may also alter the risk of the offspring for obesity. For example, offspring of female mice fed an obesogenic diet (40% energy safflower-seed oil) during pregnancy had an increased mammary tumour incidence following chemical induction. Maternal overnutrition led to increased adipogenic, lipogenic and adipokine gene expression in fetal adipose tissue and maternal high-fat diet during pregnancy and lactation altered hepatic expression of IGF-2 and key microRNA in the adult offspring. Conversely, undernutrition during pregnancy was associated with increased risk for obesity and hyperphagia in the offspring, which may confer increased risk for breast cancer. Several studies have shown that if the fetus were exposed to maternal diabetes, a frequent consequence of obesity, there would be increased obesity in the offspring.

Epigenetics

There is a critical need for research in epigenetics related to obesity and breast cancer development. A compelling study demonstrated an effect of dietary methyl supplementation, which is used in methylation pathways, during the fetal period in preventing the development of obesity through generations of agouti mice. Unfortunately, mammary tumour development was not assessed in this study. Another study using male Wistar rats showed that a high-fat diet was capable of methylating CpG sites at the leptin promoter and was associated with a reduction of the level of circulating leptin in rats that became obese.

It has been emphasised by others that it will be particularly important to focus on life in utero in light of the relationship of fetal growth with obesity and breast cancer. Notably, the review of studies on birth weight and breast cancer risk by Michels & Xue pointed to the loss of imprinting of IGF-2 and high expression level of this stimulator of breast epithelial cell proliferation in women with high birth weight. However, the mechanism by which IGF-2 expression is epigenetically altered remains to be deciphered.

In conclusion, there is substantial evidence in animal and human models to support an impact of obesity on breast cancer. Clearly, dietary patterns such as macronutrient intake including alcohol, high-fat diet and carbohydrates, insulin sensitivity as well as micronutrients influence the development and maintenance of an obese status. Thus, the bearing of obesity on breast cancer risk may be due to the obese state and/or the dietary effect.
on obesity. There are multiple potential mechanisms that may mediate breast cancer risk associated with obesity and determining which mechanism is predominant will be a challenge. An important aspect to investigate is the potential epigenetic component of the risk brought by obesity, suggested by the impact of maternal exposures on the risk for the offspring to develop breast cancer.

**Relationship of dietary patterns: healthy or Western?**

A body of literature has focused on determining the relationship between dietary patterns and breast cancer development. Dietary patterns are comprised of a variety of dietary components that are prevalent in specific diets. Dietary components may function individually or in combination within the food matrix, hence increasing their impact. Generally, the dietary patterns investigated are a prudent or healthy dietary pattern (high in vegetables and/or fruits, poultry, fish, low-fat dairy products and/or whole grains) as compared with the Western diet or so-called unhealthy diet (red or processed meats, refined grains, sweets and/or high-fat dairy products). The results of epidemiological studies are inconsistent, with a variety of reports supporting that dietary patterns with fruit and vegetable intake or high-fibre–low-fat intake are inversely associated with breast cancer risk when comparing lowest to highest intake while other reports find no association.

**Epidemiological studies**

In a review of the literature by the WCRF, the evidence was not convincing that a healthy diet conferred protection from breast cancer. Consistent with this review, results of the large European Prospective Investigation into Cancer and Nutrition (EPIC) study (n > 360,000 women) demonstrated no relationship between breast cancer incidence and fruits and vegetable intake. Contrasting results for a prudent/healthy diet were shown in a subsequent meta-analysis completed with strict inclusion criteria. From the sixteen studies used, it was concluded that a prudent/healthy dietary pattern conferred a reduced risk of breast cancer in the highest intake compared with the lowest intake categories, with an OR of 0·69 (95 % CI 0·51, 0·93) as compared with the Western diet or so-called unhealthy diet (red or processed meats, refined grains, sweets and/or high-fat dairy products). The results of epidemiological studies are inconsistent, with a variety of reports supporting that dietary patterns with fruit and vegetable intake were associated with breast cancer risk when comparing lowest to highest intake while other reports find no association.

**Animal models**

Generally, animal studies indicate that diets rich in fruits and vegetables, including cruciferous vegetables, protect against mammary tumour development. Because of the complexity of the nutrients and non-nutritional components in the diet, several underlying mechanisms have been suggested to prevent mammary tumours including antioxidant capability, protection against DNA damage, detoxification of carcinogens, and inhibition of specific cellular pathways that control proliferation, apoptosis and angiogenesis. Animal studies are strengthened by cell culture-based studies showing that specific components of these diets, such as isothiocyanates, which are capable of inhibiting histone deacetylase and thus could have an epigenetic effect, and indoles found in cruciferous vegetables, can limit cellular pathways characteristic of tumour progression. The discrepancy between animal studies showing a positive impact of diets rich in fruits and vegetables to inhibit mammary tumours, and the epidemiological studies showing mixed results, is potentially based on the limitations discussed above for population studies (i.e. the ability to measure dietary intake,
the interaction with other lifestyle factors, the genetic and epigenetic make-up (or status), and the timing of exposure.

**Intervention trials**

The Women’s Health Initiative is a randomised dietary intervention study in which postmenopausal women were counselled to reduce dietary fat intake and increase consumption of fruits and vegetables (n 48 835), with an average 8·1-year follow-up period(116). Overall, there was a small (9 %), non-significant reduced risk for invasive breast cancer in the intervention group compared with the control group(116). The intervention reduced the incidence of invasive breast cancer only in women with a high fat intake at baseline and the risk was significantly reduced only for PR– tumours and independent of ER status. In a randomised controlled multi-site (thirty-nine centres) intervention trial (n 2437) in women following early-stage breast cancer, lower fat intake (and thus energy intake) was accompanied with a 24 % reduction in recurrence risk, with an even greater impact on women with ER– cancer (42 % lower risk). Another randomised control trial to reduce fat intake and increase carbohydrate intake in which women were followed for 10 years had no effect of fat intake, but there was an increased risk of ER+ breast cancer with lower carbohydrate intake(117). However, the limitations of these trials in terms of a true link to dietary fats include maintenance of compliance to the intervention, inability to decipher confounding factors such as obesity and energy intake and the time or period of exposure. Indeed, regarding the latter, the intervention may be far later than when diet may be most effective in protecting the breast, such as during fetal development and adolescence. It is also important to note that this particular trial was focused on breast cancer recurrence, which might not be comparable with intervention studies on women who have never had breast cancer as the breast tissue will have undergone treatments and possible tumour field effects (i.e. modifications in normal tissues induced by paracrine and other micro-environmental effects from an adjacent cancer).

**Epigenetic studies**

There are few studies in this area and the ones that exist focus either on the impact of specific dietary patterns on epigenetic marks globally or on very specific organs excluding the breast. A study relating a vegetarian lifestyle and DNA methylation did not reveal any significant association(118). In contrast, preliminary reports from animal studies indicated an effect of prenatal protein-restricted diet on the methylation of specific CpG dinucleotides in the PPARα gene promoter in the liver(119). Studies such as this reveal the profound impact that maternal diet has on epigenetic make-up in the offspring and sets the course for susceptibility to certain diseases(120).

**Soya intake**

**Epidemiological studies.** Overall, there is a significant record of research studies on the impact of soya intake on breast cancer. Generally, epidemiological studies suggest that higher soya isoflavone intakes are associated with lower breast cancer risk, though not all are supportive(121–123). For example, in Asian populations where soya consumption is high, the incidence of breast cancer was found to be lower than in other cultures with low soya intake levels(124). Daughters of Asian women who immigrated to countries with Western cultures have had a higher risk of developing breast cancer than either their mothers or their grandmothers(125). A meta-analysis that included eighteen studies suggested that soya intake was inversely associated with breast cancer risk in women from the West, particularly in premenopausal women, but not in women from Asia(126). However, the results of another meta-analysis supported that women from the West (with low soya intake ranging from 0·8 to 0·15 mg soya isoflavone per d) were not protected by greater soya intake; however, Asian women, including both Asian and Asian-American women, had a reduced breast cancer risk if they increased soya intake (comparing the lowest level of soya intake ≥ 5 mg/d, OR 0·71, 95 % CI 0·60, 0·85 and intake ≥ 20 mg isoflavone/d)(121). Therefore, the results of the epidemiological studies investigating the relationship between soya intake and breast cancer risk remain controversial.

Interestingly, a number of studies have investigated the relationship between soya intake during childhood and adolescence and the risk of breast cancer development later in life. In a case–control study by Korde et al.(127) employing 966 controls and 597 cases selected among Asian-American women, childhood, adolescent and adult intakes were associated with a significantly reduced breast cancer risk among women who consumed the highest level of soya, with intakes during childhood showing the strongest and most consistent relationship with breast cancer risk (OR 0·40; 95 % CI 0·18, 0·83). These results are similar to other case–control studies which provide further evidence to support the importance of soya intake during adolescence as they showed that adolescent soya intake was inversely associated with breast cancer risk(128) in both pre- and postmenopausal women(129).

A recent meta-analysis including fourteen studies revealed that soya isoflavone intake was associated with a significant reduction of breast cancer risk in Asian populations (OR 0·76; 95 % CI 0·65, 0·86) but not in Western populations (OR 0·76; 95 % CI 0·87, 1·06)(120). Thus, the results of epidemiological studies relating soya intake to breast cancer risk are not clear, and the impact may depend on genetics/epigenetics, prior soya intake, timing of exposure and level of soya intake.

---

D. Teegarden et al.
Animal and cell models

A variety of studies in animal models with chemically induced cancer showed that soya proteins reduced mammary tumour incidence (131–139). The active component proposed to mediate the effect on breast cancer is genistein, a metabolic product of soya, which is structurally very similar to oestradiol and activates α- and β-ER. Genistein is shown to prevent mammary tumours in animal models (131–136,139) including xenograft models (140), although results are contradictory (141). Soya protein intake does not alter characteristics of mammary epithelial tissue that are associated with breast cancer risk, including proliferation, epithelial area and apoptosis, in premenopausal female monkeys (142). Similar to epidemiological studies, results with animal studies support that soya and genistein may reduce tumour progression in premenopausal mouse models (33,34). However, soya and genistein promote tumorigenesis in postmenopausal rodent models (55,56). These observations suggest a link between oestrogen pathways and the effect of soya. An added level of potential variability for the effect of soya is shown by the fact that chemoprevention by genistein in carcinogen-induced mammary cancer in rats is dependent on the diet matrix (145).

A number of mechanisms have been proposed to explain the action of genistein on tumorigenicity. As mentioned above, one of the more studied mechanisms is through oestrogen-dependent pathways, as there is substantial evidence that genistein has oestrogenic activity. However, other mechanisms may play a role, as soya intake in adulthood does not influence oestrogenic effects in non-human primates (142). Other possible mechanisms of the impact of genistein on breast tumorigenesis include inhibition of epidermal growth factor receptor tyrosine kinase activity and of topoisomerase II activity, antioxidant properties, regulation of eicosanoid metabolism, and cell-specific effects such as cell cycle progression arrest, induction of apoptosis, and inhibition of angiogenesis (144–146).

Clinical trials

There are a number of randomised clinical intervention trials for soya or isoflavones in which mammographic density was used as a marker for breast cancer risk. A meta-analysis of eight randomised controlled isoflavone intervention trials which extended from 6 months to 3 years suggested that there was no overall effect of dietary isoflavones on breast density, although isoflavone intervention led to a small increase in mammographic density in premenopausal women (147). Because of the potential for oestrogenic activity, it is of particular concern that soya isoflavones may increase the risk of breast cancer in postmenopausal women, in particular for the development of ER+ tumours. A randomised clinical 2-year isoflavone supplementation trial in 358 postmenopausal women showed no modification of breast density (148). Other 1-year (149) and 3-year (150) randomised clinical trials in postmenopausal women also showed no effect. Similarly, a 2-year soya intervention trial in premenopausal women did not change mammographic density (151). Overall, clinical trials do not support an impact of soya on breast density; however, there is still too little information from intervention trials to determine the impact of soya specifically on breast cancer development.

Epigenetic studies

In regards to epigenetics, there is much to learn from soya and related compounds. As for other nutrients, the modulation of gene expression, notably that controlled by oestrogen, occurring upon exposure to soya suggests that epigenetics-mediated effects might be involved in alterations in breast cancer risk. Furthermore, the effects of soya may differ given the time of exposure and have a long-lasting impact on the offspring. For example, exposure during pregnancy to oestrogen or genistein in rodents increases the risk of mammary cancer among the offspring (152–154). In contrast, results suggest that prepubertal genistein exposure may increase differentiation of the mammary ductal system (64), resulting in reduced breast cancer risk (98).

One possible molecular mechanism of soya action is through the Wnt/β-catenin signalling pathway that regulates progenitor cells. Indeed, overactivity of this pathway leads to excessive mammary out-growth (29). As Wnt/β-catenin is one of the pathways affected by genistein/soya, early-life exposure to soya may affect later breast cancer risk by influencing the differentiation and, thus, the epigenome of progenitor cells proposed to be involved in mammary tumour development (155). The hypothesis of a strong epigenetic impact of soya is supported by a study in which maternal exposure to genistein increased methylation of six cytosine-guanine sites upstream of the transcription start site of the Agouti gene in yellow Agouti mice (156), enhancing the number of Agouti offspring that exhibited the pseudo agouti phenotype linked to lowered cancer risk. Genistein exposure also negated the DNA hypomethylating effect of an endocrine disruptor, bisphenol A (157).

The few studies that have focused on the impact of foods on the epigenome in human subjects are quite revealing when investigating soya isoflavones. Work conducted with breast cancer-free premenopausal women using cells acquired by ductal lavage showed a correlation between soya isoflavone intake over one menstrual cycle and the induction of dose-specific modifications in the methylation of promoters of proliferation regulatory genes (RARβ2 (retinoic acid receptor B2) and CCND2 (cyclin D2)) associated with breast cancer development (158). The fact that other genes analysed showed no significant epigenetic alteration suggests that the type of
foods might have a selective epigenetic effect, and/or that in this particular and relatively homogeneous population of women, the other genes were not receptive to epigenetic modifications possibly due to the status of the mammary gland. In any case, real progress in understanding how foods might have an impact on breast cancer risk requires the identification of all specific genes that might be epigenetically modified. Additional candidate genes include cell cycle checkpoint gene p16, implicated in breast cancer development and the promoter of which might be differentially methylated depending on genistein. Noteworthy, RARB and p16 are also influenced by dietary factors such as folic acid and resveratrol. Moreover, soya isoflavone ingested by premenopausal women has been associated with increased methylation of genes coding for IGF-2 and cyclin G2 in mammary epithelial cells. Thus, soya-related compounds could possibly prevent the expression of a number of genes associated with cell proliferation.

Macronutrients

Alcohol: epidemiological studies. The only dietary factor identified by the WCRF analysis for which there was convincing evidence for its association with increased breast cancer risk beside obesity in postmenopausal women is alcohol intake. An overwhelming number of epidemiological studies, including the Women’s Health Initiative and postmenopausal women (stage I–IV), have provided support for the positive relationship between alcohol, including wine, and breast cancer risk. An intake of two or more alcoholic drinks per d for the past 5 years confers about an 82 % increase in risk compared with no alcohol consumption. Another estimate is that each additional 10 g alcohol per d increases the risk of breast cancer approximately by 10 % based on two meta-analyses. According to the European Prospective Investigation into Cancer and Nutrition (EPIC) study, a 3 % increase in risk is associated with 10 g/d of recent alcohol intake. However, like for the results related to dietary patterns and obesity, the relationship may be modified as a function of the tumour type since breast cancer risk is associated with alcohol in ER+ tumours.

Alcohol: mechanisms

The mechanism underlying the relationship between alcohol consumption and breast cancer risk has not been clearly defined. However, the action of alcohol consumption on breast cancer risk might be linked to the induction of endogenous oestrogen levels. For example, consumption of approximately one to two alcoholic drinks per d increases oestrogen levels in premenopausal and postmenopausal women. Moreover, a metabolite of alcohol, acetaldehyde, has genotoxic action that may contribute to the development of cancer.

Alcohol is also a solvent, notably for tobacco carcinogens, and may allow greater permeability of carcinogens across cell membranes. Alcohol has also been proposed to modulate enzymes involved in carcinogen metabolism, increase the production of reactive oxygen species and inhibit DNA repair. Thus, there are a variety of mechanistic pathways that may explain the relationship between alcohol and breast cancer and support epidemiological studies.

Alcohol: epigenetic studies

Epigenetic studies have revealed a trend towards decreased methylation in a cluster of cancer-related genes in primary tumours of 162 women (stage I–IV), suggesting that alcohol consumption may lead to epigenetic modifications. Another study on DNA methylation profiles in breast tumours has reported that exposure to alcohol seems associated with a specific DNA methylation pattern. Therefore, the evidence supporting an impact of alcohol on breast cancer risk seems convincing, but understanding the relationship between alcohol intake and epigenetic modifications is necessary to unravel the basis for an effect on tumour development.

Fat intake: epidemiological studies

A correlation between high-fat diets and risk of cancer has been noted for more than two decades. The WCRF did not find convincing evidence for a relationship between dietary fat intake and breast cancer risk; however, the support resource shows in the meta-analysis of twelve case–control studies, there was a positive association between breast cancer risk and saturated fat intake. In contrast, the results of a meta-analysis of eight prospective trials did not support a strong association between breast cancer incidence and total fat. Not all studies associate increased intake of total fats with increased breast cancer risk, but these studies have shown relationships with other cancer sites.

Certainly, one of the issues that complicates any epidemiologically based study is that fat intake is comprised of a variety of fats, including animal or saturated fats, polyunsaturated fats such as n-3 or n-6 PUFA, MUFAs and trans-fatty acids. Fatty acid types have differential effects on the progression of diseases and different mechanisms of action. Therefore, each of the family of fats, or individual fatty acids, may have a different impact on the development and progression of breast cancer. Unfortunately, the ability to measure the dietary levels of fatty acids accurately is very limited. It is not surprising then that studies produce opposite results. For example, the European Prospective Investigation into Cancer and Nutrition (EPIC) study showed that a high intake of SFA, MUFA, n-3 PUFA
and n-6 PUFA led to a two-fold increase in breast cancer risk when comparing highest to lowest tertiles of processed meat, animal fats and margarine (n=15,351 with an average follow-up of 6 years)\(^{(187)}\). No association could be noted between breast cancer risk and specific fatty acids or fat intake patterns\(^{(187)}\). Similar inverse associations were made for a meta-analysis of prospective studies on animal fat\(^{(188)}\). Furthermore, inverse associations were found between breast cancer risk and dietary patterns relying on animal product intake as well as dietary patterns rich in unsaturated fat\(^{(189)}\). Data obtained using the lipidome approach (i.e. an integrated view of the complex lipid interaction or lipid profile based on adipose tissue samples) suggested that elevated MUFA intake and a low n-6:n-3 fatty acids ratio intake were associated with decreased breast cancer risk\(^{(189)}\). In contrast, trans-fatty acids, for which the main source is industrial hydrogenation processing (for example, margarine), have been linked to an increase in breast cancer risk\(^{(190)}\). Results of the Nurses’ Health Study, in a 20-year follow-up, showed no association between fats and breast cancer risk, even when specific types of fat, and ER or PR status were considered\(^{(191)}\). However, fat intake during adolescence may have to be further investigated, as the RR for breast cancer in premenopausal women in the Nurses’ Health Study was 1.35 in the highest quintile of dietary fat and distribution of lipid rafts\(^{(200)}\) and the level of oxidative stress. Specific types of fat, provided with the diet and normally stored in cell membranes, are metabolised very differently in cells, serving not only as an energy substrate that can alter membrane susceptibility to lipid oxidation, but also produce biologically active signals. For example, arachidonic acid and EPA are precursors for eicosanoids, which are potent intracellular signals. More specifically, n-3 fatty acids can inhibit inflammatory mediators that are proposed to promote cancer progression. Different types of lipids may differentially affect breast cancer risk, and the mechanisms involved are likely to also differ depending on the type of lipid\(^{(201)}\). The biological effects of n-6 PUFA and n-3 PUFA proposed to promote and suppress cancer progression, respectively, are diverse and include characteristics of cells such as proliferation and apoptosis, as well as an influence on angiogenic factors\(^{(202)}\) that play a critical role in cancer development and progression. Interestingly, a high dietary intake of n-6 PUFA during pregnancy increases mammary tumorigenesis in the offspring in rats\(^{(152)}\), suggesting a long-lasting effect of fats on cancer risk. Another link with mammary cancer susceptibility was found in a study focused on a high-fat diet in rats, a diet which has been linked with increased incidence of induced mammary tumours in the offspring\(^{(203)}\). Interestingly, the normal mammary tissue of offspring from mothers fed a high-fat diet during pregnancy was altered, with denser epithelial tree and higher number of proliferating cells compared with controls. The offspring of high-fat diet-fed mothers had higher birth weight and displayed shorter latency for mammary tumour development. Thus, there is a mechanistic basis for the purported relationship between several specific fatty acids and breast cancer risk. However, deciphering the mechanisms will require well-defined models in order to later on translate these results into population studies and interventions.

**Fat intake: animal studies**

Consistent with epidemiological data in human subjects, a significant body of literature shows that diets high in fat increase the progression of mammary tumours in rodents\(^{(193,194)}\). Rodent studies consistently show that a high-fat diet promotes hyperproliferation in the mammary gland, and shortened latency and increased incidence of carcinogen-induced mammary tumours\(^{(195,196)}\). As noted above, the interpretation of these studies is complicated by greater adiposity and excess energy intake associated with the intake of high-fat diets. When energy intake is controlled in animal studies, the effect of fat intake is weak or eliminated\(^{(197,198)}\), suggesting that energy intake may be the most important factor for breast cancer risk.

**Fat intake: mechanisms**

Multiple mechanisms are proposed to underlie an impact of fats on breast cancer, but the specific pathways remain unclear\(^{(199)}\). Enrichment of cell membranes with dietary fats may alter membrane fluidity and potentially the size and distribution of lipid rafts\(^{(200)}\) and the level of oxidative stress. Specific types of fat, provided with the diet and normally stored in cell membranes, are metabolised very differently in cells, serving not only as an energy substrate that can alter membrane susceptibility to lipid oxidation, but also produce biologically active signals. For example, arachidonic acid and EPA are precursors for eicosanoids, which are potent intracellular signals. More specifically, n-3 fatty acids can inhibit inflammatory mediators that are proposed to promote cancer progression. Different types of lipids may differentially affect breast cancer risk, and the mechanisms involved are likely to also differ depending on the type of lipid\(^{(201)}\). The biological effects of n-6 PUFA and n-3 PUFA proposed to promote and suppress cancer progression, respectively, are diverse and include characteristics of cells such as proliferation and apoptosis, as well as an influence on angiogenic factors\(^{(202)}\) that play a critical role in cancer development and progression. Interestingly, a high dietary intake of n-6 PUFA during pregnancy increases mammary tumorigenesis in the offspring in rats\(^{(152)}\), suggesting a long-lasting effect of fats on cancer risk. Another link with mammary cancer susceptibility was found in a study focused on a high-fat diet in rats, a diet which has been linked with increased incidence of induced mammary tumours in the offspring\(^{(203)}\). Interestingly, the normal mammary tissue of offspring from mothers fed a high-fat diet during pregnancy was altered, with denser epithelial tree and higher number of proliferating cells compared with controls. The offspring of high-fat diet-fed mothers had higher birth weight and displayed shorter latency for mammary tumour development. Thus, there is a mechanistic basis for the purported relationship between several specific fatty acids and breast cancer risk. However, deciphering the mechanisms will require well-defined models in order to later on translate these results into population studies and interventions.
indicate that fatty acid treatment that protects the normal phenotype also globally has an impact on the level of a number of histone modifications (K McDole and S Lelièvre, unpublished results). It will be important to identify which modifications are sustained and the specific genomic regions involved.

Carbohydrates, glycaemic index and glycaemic load: epidemiological studies

Carbohydrates and carbohydrate quality could influence breast cancer risk potentially by affecting insulin resistance and plasma levels of insulin and glucose\(^ {210}\). To date, twelve prospective cohort studies have shown inconsistent associations between total carbohydrate, glycaemic index, glycaemic load and breast cancer\(^ {210}\). Nevertheless, data from Mexico, where carbohydrates account for close to 64 % of energy intake in the population, support an association between carbohydrate intake as well as glycaemic load and breast cancer among pre- and postmenopausal women\(^ {207}\). High intake of refined carbohydrates may have stronger associations with breast cancer risk in populations genetically susceptible to insulin resistance, such as in Mexico, particularly when combined with obesity and low levels of physical activity\(^ {208}\). Further, a higher glycaemic index during adolescence is associated with an increased risk for breast cancer in adults in the Nurses’ Health Study II\(^ {209}\). In addition, carbohydrate quality may differently affect breast tumour types including positive associations of carbohydrate intake, glycaemic index and glycaemic load with risk of ER+ /PR− breast cancer, but not ER+/PR− or ER−/PR− breast tumour\(^ {210}\), or an increased risk of ER− breast cancer\(^ {211,212}\). Thus, evidence of an association between carbohydrate intake, glycaemic index and glycaemic load is conflicting and may be confounded by insulin resistance and the type of tumour.

Carbohydrates, glycaemic index and glycaemic load: mechanisms

The mechanisms underlying the relationship between carbohydrate intake, and particularly glycaemic index, and breast cancer risk is proposed to be through greater insulin action. Chronically raised insulin levels may increase carcinogenesis in breast tissue by directly stimulating insulin receptors. Insulin can also reduce plasma and tissue levels of IGF-binding proteins 1 and 2, which may in turn increase the availability of IGF-1\(^ {213}\), and experimental studies have revealed strong proliferative and anti-apoptotic effects of IGF-1 in breast tissue\(^ {213}\). A recent pooled analysis including seventeen prospective studies reported a positive association between IGF-1 and the risk of developing ER+ tumours (OR 1·38; 95 % CI 1·14, 1·68; comparing highest with lowest fifth)\(^ {214}\). Therefore, potential mechanisms to explain the impact of carbohydrates on breast tumour development include higher insulin levels (similar to obesity) and increased availability of IGF-1, both of which activate cellular responses consistent with cancer progression.

Carbohydrates, glycaemic index and glycaemic load: epigenetics

Similar to fatty acids, the specific effect of carbohydrates on the epigenome has not been examined. Most studies currently available are linked to obesity. As mentioned above, specific three-dimensional cell models that mimic phenotypically normal breast glandular differentiation might be an interesting first approach to sort out epigenetic effects directly related to carbohydrates.

Micronutrients

Research pertaining to elements required in minute amounts in the diet has generated many reports, particularly in regards to an effect on epigenetic mechanisms. Among the most studied elements for breast cancer are folate, vitamin D and carotenoids.

Folate: epidemiological studies

Most prospective studies do not provide evidence of an association between folate intake and breast cancer risk\(^ {215–217}\). In contrast and consistent with the literature related to colorectal cancer\(^ {218}\), there is also evidence to support that folate supplementation may increase the risk for breast cancer\(^ {219}\). Interestingly, a benefit from folate intake is observable in individuals with low folate status (in non-vitamin users, highest (356 \(\mu\)g/d) vs. lowest (≤159 \(\mu\)g/d), OR 0·61; 95 % CI 0·41, 0·93), suggesting a protective effect against breast cancer only in non-supplemented vitamin B users\(^ {220}\). Protective effects have also been observed in populations with low folate status, in which vitamin supplementation is infrequent\(^ {221–225}\).

In a case–control study conducted among Mexican populations, women with the highest folate intake (mean \(454 \mu\)g/d) compared with women with the lowest intake (mean \(224 \mu\)g/d) had a risk for breast cancer of 0·64 (95 % CI 0·45, 0·90)\(^ {220}\). Furthermore, vitamin B\(_{12}\), a co-enzyme in folate metabolism, might be associated with a lower risk of breast cancer and low vitamin B\(_{12}\) intake may reduce the potential protection conferred by folate against breast cancer development\(^ {219,221,222,227}\).

Folate studies are further complicated by the fact that, as for other dietary components, additional factors may have an impact on the relationship between folate intake and breast cancer risk. For example, an inverse association between breast cancer development and circulating folate levels among alcohol drinkers has been noted\(^ {216,228}\). Ethanol may induce a physiological deficiency that affects the one-carbon metabolism involved in the epigenetic control of gene transcription by reducing folate absorption.
from the gastrointestinal tract or by inhibiting enzymic activity\(^\text{218}\). The impact of folate may also be related to the tumour type, since the incidence of ErbB2-positive breast cancers is increased in women in the highest tertile of plasma folate compared with the lowest\(^\text{229}\).

Folate: animal models

The impact of folic acid on the initiation and progression of mammary tumorigenesis in animal models is complex and dependent on the dose and timing of dietary manipulation. Generally, studies in animal models support that folate deficiency is associated with a reduced risk of developing mammary tumours, although some studies show no effect when dietary intervention is initiated before chemical induction of tumorigenesis\(^\text{219,230–252}\). On the other hand, folate deficiency developed after tumour initiation is shown to inhibit the progression of mammary neoplasia\(^\text{253–255}\), suggesting that high-folate diets may enhance the progression of tumours.

Folate: mechanisms

Knowing the mechanisms of folate impact on the mammary gland would help greatly in deciphering how to integrate this nutrient in prevention studies. As mentioned above, epidemiological studies suggest an interaction between alcohol intake and folate on risk of cancers, and there is a mechanistic basis for this observation, as alcohol has an impact on folate metabolism\(^\text{236}\). Overall, the results suggest that folate deficiency may increase initiation, but decrease progression of breast cancer, which is consistent with the concept first proposed for colon cancer that folate prevents the development of cancers, but high folate intake may promote progression of already established tumours\(^\text{218}\). This discrepancy might in part be explained by epigenetic effects.

Folate: epigenetics

Folate is a central player in one-carbon metabolism, including methylation of DNA. It is converted to 5,10-methylene-tetrahydrofolate (MTHF), the metabolites of which are important for the synthesis of DNA components, guanine and adenine. Importantly, the product of MTHF reductase, 5-methyltetrahydrofolate, is a methyl donor for the conversion of homocysteine to methionine, which ultimately serves in the form of S-adenosylmethionine for a variety of reactions, including methylation of DNA. Polymorphism in MTHF reductase has been shown to interact with B vitamins to modulate breast cancer risk\(^\text{220}\). Indeed, there is evidence that folate deficiency may lead to global hypomethylation\(^\text{220}\). Thus, there is a strong mechanistic basis for a role of alterations in dietary intake levels of folate in the initiation and progression of breast cancer by acting on DNA integrity, synthesis, repair and methylation.

So far, studies have suggested that folate may confer protection in early carcinogenesis and also promote cancer growth later during the neoplastic process, including that of mammary tumours\(^\text{219,237}\). This is a plausible scenario because, as the disease progresses, the organisation of the cell nucleus, including the genome, may be modified\(^\text{12}\). Therefore, one-carbon metabolism-mediated DNA methylation triggered by folate might affect genes that are protecting against breast cancer development as well as genes that are promoting tumour development and progression depending whether or not nuclear organisation renders these genes accessible for epigenetic modification.

One critical way for nutrients to affect the epigenome is to influence the availability of methyl groups. By doing so they could modify the methylation status of DNA and, thus, gene transcription\(^\text{45}\). In the preceding paragraph, it was explained that folate contributes to the one-carbon metabolism pathway\(^\text{238}\). Particularly, folate carries a methyl group used for the synthesis of the methyl donor metabolite S-adenosylmethionine\(^\text{239}\), and could also make an impact on the activity of methyltransferase via S-adenosylhomocysteine\(^\text{45}\). As a result, bioactive foods can modify the epigenetic landscape, possibly leading to permanent gene silencing.

The epigenetic effect might also be critical for the influence of maternal diet on the offspring. Folate supplementation before and during pregnancy in rats increased the risk of tumour development induced chemically by 7,12-dimethylbenz(a)anthracene (DMBA) in the offspring compared with a control (adequate) diet, and induced a decrease in global DNA methylation\(^\text{240}\). Folate supplementation during pregnancy and weaning reduced the number of mammary terminal end buds, a marker of breast cancer risk, suggesting a protection from breast cancer compared with a control diet\(^\text{241}\). The potential link between terminal end bud density and an effect on DNA methylation by folate remains to be clarified. In humans, it is also possible to influence methylation in the offspring via nutritional changes in the mother. For instance, studies have shown that folic acid supplementation of women during the periconceptional time increases IGF-2 gene methylation in children\(^\text{242}\).

The broad mechanisms by which foods seem to influence the epigenome (for example, via one-carbon metabolism and methyltransferase activity) could potentially affect many genes. Indeed, a minimum of 60% of genes are proposed to be methylated. Also a majority of genes will be sensitive to acetylation and methylation of histones. Yet, as shown with the example of folate, only certain genes seem to be responsive to the modulation of common epigenetic pathways. A plausible hypothesis is that only genes in a receptive chromatin environment will respond to such broad epigenetic modulation. Therefore, probably the effect of dietary compounds will depend on the gene, the cell type (with its specific nuclear
organisations\(^{245}\), the cell status (i.e. proliferation) and previous epigenetic conditions. For instance, deprivation of folate has been associated with gene hypermethylation specifically in the liver in a rat model\(^{230,244}\). Timing might also be important, as the effect of folate might be opposite depending on when it is given. For instance, it stimulates tumour development if a preneoplastic lesion is already in place\(^{245}\). Therefore, promoting or preventing methylation and acetylation reactions via foods could have various outcomes depending on when during life such an influence occurs. Of particular interest is the consequence of diet received before mammary gland development on epigenetic modifications and breast cancer risk.

Overall, there is evidence of a biphasic effect of folate deficiency and supplementation on breast cancer risk depending on the timing of dietary intervention and involving epigenetics, but the results remain controversial and the underlying mechanisms are not definitively determined.

**Vitamin D**

Vitamin D is one of the most studied micronutrients as a cancer-preventive agent, but the controversy regarding its potential use in prevention is not yet settled. A main reason is that, like for folate, the efficacy of vitamin D may depend on individual baseline level, dose and supplementation period.

**Vitamin D: epidemiological studies**

Results from many epidemiological studies support that vitamin D is associated with reduced breast cancer risk\(^{246,247}\). First were ecological studies showing a relationship between exposure to UV light and reduced risk of breast cancer\(^{248}\). The potential explanation for this relationship is that vitamin D is synthesised in the skin under the influence of UV light. Both UV light-produced vitamin D and dietary vitamin D are then converted in the liver to 25-hydroxyvitamin D (25OHD), the serum levels of which are used as a vitamin D status marker. In a pooled analysis, the results revealed that 25OHD serum levels of approximately 52 ng/ml were associated with a 50% reduction in breast cancer risk compared with women with 25OHD levels < 13 ng/ml\(^{240}\). One case–control study revealed that women with 25OHD plasma concentration < 50 nmol/l had five times greater risk of developing breast cancer than women with concentrations exceeding 150 nmol/l\(^{240}\). Similarly, a meta-analysis reported a 45% decrease in breast cancer risk among women in the highest quartile (60 nmol/l) of circulating 25OHD compared with women with the lowest level\(^{250}\). Epidemiological studies have also shown an inverse association between vitamin D intake or serum 25OHD and breast cancer development, in both premenopausal women\(^{251,252}\) and postmenopausal women\(^{253}\).

Similar to other dietary components, menopausal status may play a role in the association between vitamin D and breast cancer risk. In an ecological study, the inverse relationship between geographical UV exposure and breast cancer was specific to premenopausal women\(^{254}\). Similarly, in the Nurses’ Health Study ( \( n \approx 90000 \) ) with an approximate 14-year follow-up, vitamin D intake was inversely associated with breast cancer risk only in premenopausal women, which is consistent with results from the Cancer Prevention Study II Nutrition Cohort. In the latter, dietary vitamin D intake was not associated with breast cancer risk in postmenopausal women\(^{255}\). Thus, although a strong body of work supports the relationship between vitamin D and breast cancer, the results of epidemiological studies remain controversial, and discrepancies noted in the relationship may be due to the influence of other factors. It is hoped that ongoing trials will take note of the many variables that could affect the outcome of the results to better pinpoint the relationship between vitamin D and breast cancer.

**Vitamin D: animal studies and mechanisms**

Vitamin D is best characterised for its role on the regulation of Ca status. High vitamin D status leads to the suppression of serum parathyroid hormone levels. Parathyroid hormone is a strong stimulator of renal 25-hydroxyvitamin D-1α hydroxylase which catalyses the conversion of 25OHD to 1,25-dihydroxyvitamin D \((1,25(OH)\_2D)\)^\(^{256,257}\), leading to an inverse relationship between vitamin D status (serum 25OHD levels) and serum 1,25(OH)\_2D. This inverse relationship is difficult to reconcile with observations that higher vitamin D status is associated with a decrease in breast cancer risk but 1,25(OH)\_2D directly inhibits cancer-relevant endpoints in cells. However, extra-renal 1α-hydroxylase enzymes have also been identified in a variety of tissues\(^{258}\) and in mammary epithelial cells\(^{259}\), which may lead to greater local production of 1,25(OH)\_2D under conditions of high vitamin D status\(^{260}\).

The activity of 1,25(OH)\_2D is regulated through vitamin D receptor (VDR)-mediated transcriptional regulation as well as rapid, non-genomic actions. The VDR, a member of the steroid hormone receptor family, mediates 1,25(OH)\_2D transcriptional actions by heterodimerising with retinoid X receptor and interacting with vitamin D response elements to up-regulate and down-regulate a wide variety of genes\(^{261,262}\). Other evidence supports that 1,25(OH)\_2D regulates kinase signalling cascades involving protein kinase C, extracellular signal-regulated protein kinases 1 and 2, phosphoinositide-3-kinase, and Src\(^{263–266}\), which are generally shown to be rapid and independent of new RNA and protein synthesis\(^{263,267}\). Consistent with the epidemiological results, there is also substantial evidence in animal models to support a protective effect of vitamin D for breast cancer\(^{268}\). For example, susceptibility to hyperplasia and tumours in the
mammary gland is greatly increased in mice lacking the VDR.\(^{(269,270)}\) Further, mammary gland proliferation and tumour development is reduced by high vitamin D intake in animals.\(^{(271,272)}\)

Overall, in vitro studies have shown that vitamin D can regulate critical characteristics of cells necessary for carcinogenesis, including inhibiting cell proliferation, promoting apoptosis and reducing angiogenesis.\(^{(273)}\) Furthermore, alterations in genes related to vitamin D metabolism have been associated with breast cancer risk.\(^{(268)}\) Thus, there is substantial evidence in both animal and cell culture studies to support that vitamin D reduces breast cancer risk. However, as for fatty acids, the translation of the information to human populations will require consideration of many factors and well-designed clinical trials.

### Vitamin D: intervention studies

The largest clinical trial in which the impact of dietary vitamin D on breast cancer development was investigated is the Women’s Health Initiative. In this study, no impact of vitamin D supplementation on breast cancer risk was noted.\(^{(274)}\) However, the levels of vitamin D supplement used in this trial (400 IU/d; 10 µg/d) are now considered potentially too low to elicit maximal effects on bone and, thus, also the proposed effect on breast cancer development. In addition, because the duration was only 7 years, this trial does not represent the testing of a meaningful intervention to prevent breast cancer. An example of the issue of timing of the intervention is shown in the study by Lappe et al., who completed a randomised placebo-controlled Ca and vitamin D intervention trial in postmenopausal women (> 55 years; n 1179), followed during 4 years.\(^{(275)}\) The RR of developing breast cancer with Ca supplementation (about 1450 mg/d) alone was 0.54, and no difference was found for the group with both Ca and vitamin D (1100 IU/d; 27.5 ìg/d), RR 0.40. It was hypothesised that vitamin D might be less effective in preventing breast cancer development if the cancer is already present, although not yet detectable with current screening methods. Therefore, women who were diagnosed with breast cancer in the first year of the trial were excluded from the analysis. In that case the risk of developing breast cancer in the vitamin D plus Ca group was significantly reduced (RR 0.23) compared with the placebo and compared with Ca supplementation alone (RR 0.59). This study provides strong evidence that vitamin D, at least in the presence of Ca, significantly reduces breast cancer risk and reveals that the timing of the intervention (i.e., before breast cancer is present) may be critical.

### Vitamin D: epigenetics

First, epigenetic modifications are suggested to alter the effects of 1,25(OH)\(_2\)D. For example, the use of inhibitors to epigenetic modifications restores signals associated with anti-proliferative effects in vitamin D-resistant breast cancer cells.\(^{(276)}\) Suppression of 1α-hydroxylase expression, which influences the production of the most active form of the vitamin, is modified in part by histone deacetylation and mediation of this repression by the VDR requires DNA methylation in the promoter of the gene.\(^{(277)}\) Further, epigenetic alterations in the gene producing the 24-hydroxylase that mediates the first step in the degradation of 1,25(OH)\(_2\)D was shown in full-term human placental tissue, but not methylation of the VDR and 1α-hydroxylase genes.\(^{(278)}\) Reduction in 24-hydroxylase expression is mediated at least in part by methylation of the promoter in human prostate cancer.\(^{(279,280)}\) Therefore, epigenetic modifications may alter the metabolism as well as the action of vitamin D, but little information is available in breast tissue. On the other hand, although the active metabolite, 1,25(OH)\(_2\)D, was shown to have an effect on gene expression in breast cancer cells,\(^{(281)}\) the role of vitamin D in modifying the epigenome in relation to breast cancer has not been explored. Nevertheless, nuclear receptors (to which the VDR belongs) and associated mediators are known to influence chromatin remodelling and epigenetic modifications. In conclusion, there is an interaction of vitamin D with the epigenome, but a consequence for breast cancer risk is not clear.

### Carotenoids: epidemiological studies

A substantial literature exists investigating the relationship between carotenoids and cancer.\(^{(46,262,283)}\) In epidemiological studies, intake of carotenoids is assessed both by dietary analysis and serum levels of the carotenoids. Some studies have indicated a protective effect of carotenoids,\(^{(284,285)}\) whereas other studies showed no association with breast cancer.\(^{(286–289)}\) The putative effect of carotenoids may be modified by age or menopausal status since an inverse association with breast cancer risk was noted in premenopausal women rather than in postmenopausal women.\(^{(290)}\) Furthermore, the potential impact of carotenoids may be greater when associated with other lifestyle factors. This is exemplified by the link between carotenoids and the reduced risk of invasive breast cancer in premenopausal, but not postmenopausal, smokers.\(^{(290)}\)

It is important to note that carotenoids are a family of compounds including retinol, retinyl palmitate, α-carotene, β-carotene, ß-cryptoxanthin, lutein and lycopene. Like fats, the type of carotenoid may have a different impact on the risk of breast cancer. A nested case-control study for women who donated blood before diagnosis revealed that women who developed breast cancer had significantly lower serum concentrations of β-carotene, lycopene and total carotene than the breast cancer-free controls.\(^{(291)}\) Similarly, serum lycopene levels have been associated with a reduced breast cancer risk.\(^{(286)}\) Contradictory results exist among the types of carotenoids as revealed by the Women’s Health Initiative since baseline serum levels of...
α-carotene and β-carotene were negatively associated, while lycopene levels were positively associated with invasive breast cancer in postmenopausal women\(^{(292)}\). Therefore, the relative levels of the different types of carotenoids are important to take into account as well as a potential influence from other lifestyle factors.

**Carotenoids: mechanisms**

A number of mechanisms have been examined that might underlie the purported relationship between carotenoids and breast cancer development. Cell culture studies show that retinoids may reduce proliferation and induce differentiation of epithelial cells\(^{(293,294)}\). Carotenoids function as antioxidants and, thus, may also protect DNA from damage induced by reactive oxygen species. On the other hand, at high doses, β-carotene may act as a pro-oxidant, hence potentially promoting tumorigenesis\(^{(295,296)}\). Therefore, although mechanisms exist to explain the relationship between carotenoids and breast cancer, there is still much to learn about the effect of these nutrients on the breast tissue.

**Carotenoids: epigenetic studies**

Lycopene has been reported to influence the epigenome by partially demethylating the tumour suppressor gene *GSTP1* (glutathione S-transferase P1) in breast cancer cells. Interestingly, treatment of non-neoplastic breast epithelial cells MCF10A with lycopene led to demethylation of *RARβ2* (retinoic acid receptor β2)\(^{(297)}\), a gene silenced before the onset of tumour development\(^{(298)}\). Although lycopene is currently classified as displaying a possible preventive action against cancer because of its influence on the epigenome, additional mechanistic studies are needed to clearly establish this possibility and will require the use of appropriate cell models.

**The complexity of epigenetics and diet interaction**

Most of the studies related to the epigenome, diet and cancer have focused on DNA methylation. Yet, as explained in the introduction, a large area of epigenetics relies on the study of histone modifications. Unfortunately, much less is known regarding the potential effect of foods and nutrients on histones. One of the rare studies suggests that resveratrol contained in red wine and possibly associated with protection against cancer development\(^{(299)}\) could lead to histone deacetylase (HDAC) inhibition via an effect on Sirt\(^1\)\(^{(300,301)}\), thus potentially promoting histone hyperacetylation and preventing transcriptional repression.

The influence of diet early in life on cancer development occurring years later has to be regarded as a ‘life-course perspective on cancer risk’ to quote Burdge *et al.*\(^{(37)}\). Indeed, it has been proposed that breast cancer might develop over 10 to 30 years; therefore it seems logical that some of the initiating events would occur early in life, even as soon as embryonic development, either because of epigenetic imprinting from the parent gametes or because of nutrition received *in utero* (or before puberty). Further emphasis on studies related to the impact of diet early in life on breast cancer development is critical. But the truth remains that not all women subjected to risk factors early in life will develop breast cancer. It is likely that the complex epigenetic profile of each individual will provide a different soil in each individual and, thus, a different response to risk factors. Yet, it is likely that variations in soils are not infinite; rather, a subset of specific genes might have to be altered to favour breast cancer development. By finding or defining the protective signature of the epigenome in the breast (i.e. an epigenetic profile that prevents tumour development), we might be able to develop ways to return to this signature once it is altered and use this signature as a method to assess preventive strategies. Indeed, it is critical to develop biomarkers of breast cancer initiation to complete cost-effective and rapid assessment of the impact of potential preventive agents on the development of the disease. It seems that understanding the link between diet, the epigenome and specific types of breast cancers might be a way to achieve this goal.

![Fig. 3. Venn diagram of a relationship between diets/food components and factors that influence their impact on breast cancer risk. Major life characteristics share specific relationships with diets/food components when it comes to breast cancer. These characteristics include the stage of mammary gland development (which encompasses menopausal status/age) and the individual’s background (race/ethnicity and lifestyle other than dietary habits). The combination of these different factors might explain why certain nutrients will have an impact on the development of a certain type of breast tumour. Such knowledge is critical for optimal primary prevention, as it suggests that (1) the study of the impact of diets/food components on breast cancer has to take into account diversity and (2) the link between the development of a certain type of breast tumour and nutrition has to be further scrutinised, notably via the identification of the early alterations in the breast specific to a given type of neoplasia. ER, oestrogen-positive; ER−, oestrogen-negative; PR, progesterone-positive; PR−, progesterone-negative.](https://www.cambridge.org/core/core/journals/nutrition-research-reviews/i/10.1017/S0954422411000199)
Conclusion

It is evident from the studies reported in the present review that there is a divergence in the results from population studies compared with more controlled conditions. There are several reasons for this lack of consensus beside the possibility of confounding factors and the many differences in the experimental design and endpoints. We need to resolve the discrepancies to launch a global effort to fight the rise of breast cancer incidence which includes diverse populations. Indeed, few studies are available from LMI countries where variability in food intake is large and nutritional supplementation less prevalent. In addition, stratification of breast cancer by specific characteristic has to be further considered, particularly breast cancer grades, receptor status (ER, PR, HER2 (human epidermal growth factor receptor-2)) and other molecular classification, as specific diets and nutrients interact with these factors to promote or protect from a defined type of breast cancer (Fig. 3). Finally, it seems that dietary factors are particularly important in determining premenopausal breast cancer risk. Efforts ought to be placed on developing studies in countries where breast cancer incidence is high in younger women.

Gene–diet interaction and long-term epigenetic mechanisms are paramount in determining breast cancer risk. Further investigations are needed in order to unravel the role of diet on long-term and temporary epigenetic modifications. On a side note, another aspect that should not be forgotten in future studies is the possibility for foods to convey environmental pollutants, some of which have hormonal activity, and which could also contribute to epigenetic changes. The endeavour of identifying the meaning of epigenetic alterations will require taking into account the complexity of histone changes. Indeed, one nutrient might have different effects depending on the chromatin environment of a specific gene. Therefore, global epigenetic modifications need to be correlated with modifications at specific gene loci and new technologies, notably microscopy-based imaging, might enable scientists to perform these studies with high-throughtput efficacy. There is increasing evidence that large-scale chromatin organisation or higher-order chromatin organisation that involves gene neighbourhoods or groups directs tissue development and differentiation. Therefore, as the epigenome is modified by environmental stimuli, many genes might change expression although only a few genes will be required to determine breast cancer development. These few genes need to be identified and their epigenetic environment scrutinised. Similarly, understanding the impact of diet on methylases and demethylases specific to certain histone modifications and on chromatin remodelling complexes involved in facilitating or preventing gene transcription would help unravel mechanisms involved in epigenetic alterations that lead to breast cancer. Animal and appropriate cell culture models should help sort through key genes for breast cancer initiation and their epigenetic susceptibility to diet. Animal models to study mammary cancer prevention are well defined but they do not always represent the behaviour of human cells. Implementing the use of powerful human cell models of phenotypically normal mammary differentiation and early stages of tumour development provided by three-dimensional cell culture, instead of using cancer cells or cells in flat monolayer culture that lack tissue morphogenesis, should bring significant information regarding the molecular mechanisms involved in the impact of food on the breast epithelium.

Acknowledgements

The present review was supported by The National Institutes of Health (R25CA128770 to D. T. and S. A. L., and R01CA112017 to S. A. L.) and the Komen Foundation for the Cure (BCTR-0707641 to S. A. L.). All three co-authors contributed to ideas and writing for this paper. The present review is part of the International Breast Cancer and Nutrition (IBCN) Project initiated at Purdue University. The authors declare no conflict of interest.

References


Diet, epigenome and breast cancer interaction


71, 57–78.
Diet, epigenome and breast cancer interaction


166. Newcomb PA, Nichols HB, Beasley JM, et al. (2009) No difference between red wine or white wine consumption...


Downloaded from https://www.cambridge.org/core. IP address: 54.70.40.11, on 10 Jul 2021 at 11:28:14, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms. 
https://doi.org/10.1017/S0954422411000199


